Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

PHASE4TerminatedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

May 21, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

August 21, 2019

Conditions
Iron OverloadSickle Cell DiseaseOther Anemias
Interventions
DRUG

Deferiprone

Trial Locations (13)

29425

Medical University of South Carolina, Charleston

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Children's Hospital of Michigan, Detroit

94609

UCSF Benioff Children's Hospital Oakland, Oakland

19104-4399

The Children's Hospital of Philadephia, Philadelphia

Unknown

Hospital for Sick Kids, Toronto

Zagazig University, Alexandria

Ain Shams University, Cairo

Cairo University, Cairo

Pediatric Hospital of Cairo University, Cairo

Asser Central Hospital, Abhā

Barts and The London, London

Evelina Children's Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT02443545 - Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias | Biotech Hunter | Biotech Hunter